DSM licenses high cell density technology to Amgen

DSM Pharmaceutical Products granted Amgen nonexclusive rights to use its patented XD high cell density process. The XD technology can be used in the production of biological products such as antibodies and fusion proteins.

View Full Article in:

Genetic Engineering & Biotechnology News · Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC